This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tessier, P. R.
Right arrow Articles by Nicolau, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tessier, P. R.
Right arrow Articles by Nicolau, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1425-1434, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1425-1434.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal Pneumonia

Pamela R. Tessier,1 Myo-Kyoung Kim,1 Wen Zhou,1 Dawei Xuan,1 Chonghua Li,1 Min Ye,1 Charles H. Nightingale,3,4 and David P. Nicolau1,2,4*

Department of Pharmacy Research,1 Division of Infectious Diseases,2 Office for Research, Hartford Hospital, Hartford, Connecticut 06102,3 School of Pharmacy, University of Connecticut, Storrs, Connecticut 062684

Received 27 February 2001/ Returned for modification 9 September 2001/ Accepted 6 February 2002

The pharmacodynamic profile of clarithromycin (CLR) was evaluated with a murine model of pneumonia. Eight Streptococcus pneumoniae isolates, including three macrolide-sensitive and five macrolide-resistant strains, were inoculated intratracheally into immunocompromised ICR mice as 108-CFU bacterial suspensions. Orally administered CLR daily doses ranging from 5 to 600 mg/kg of body weight were given over 5 days, during which animal survival was monitored. The bacterial density in lung tissues was examined after 24 h of CLR treatment and in control groups. Pharmacokinetic analysis of CLR in mice demonstrated that the regimen of 150 mg/kg twice a day was representative of human pharmacokinetics and was used to compare the efficacy of CLR against sensitive and resistant S. pneumoniae strains. Immunocompetent CBA/J mice were also infected and treated as described above and evaluated for bacterial density and survival to assess the effect of the presence of leukocytes. All three pharmacodynamic parameters, the duration (percent) of the time that serum CLR concentrations remain above the MIC (%T>MIC), the ratio of the area under the concentration-time curve from 0 to 24 h (AUC0-24) to the MIC, and the ratio of the maximum concentration of drug in serum to the MIC, were found to be closely correlated to CLR bacterial efficacy (P < 0.001). Furthermore, all parameters had close correlation to bacterial density (r2 = 0.72 to 0.82), median survival (r2 = 0.93 to 0.94), and total percent survival (r2 = 0.91 to 0.92). These in vivo data suggest that the bacterial activity of CLR is closely correlated with all three parameters over a wide range of exposures and, as a consequence of parameter interdependency, AUC0-24/MIC is the most reasonable predictor of antibiotic efficacy. In this neutropenic pneumonia model, CLR was less efficacious against S. pneumoniae strains for which MICs were >=4 µg/ml. However, the presence of leukocytes in the immunocompetent mice resulted in improved bactericidal activity, relative to that in the neutropenic animals, despite an MIC of 4 µg/ml.

* Corresponding author. Mailing address: Division of Infectious Diseases, Hartford Hospital, 80 Seymour St., Hartford, CT 06102-5037. Phone: (860) 545-3941. Fax: (860) 545-3992. E-mail: dnicola{at}harthosp.org.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1425-1434, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1425-1434.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Abduljalil, K., Kinzig, M., Bulitta, J., Horkovics-Kovats, S., Sorgel, F., Rodamer, M., Fuhr, U. (2009). Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration. Antimicrob. Agents Chemother. 53: 2892-2901 [Abstract] [Full Text]  
  • Chiavolini, D., Pozzi, G., Ricci, S. (2008). Animal Models of Streptococcus pneumoniae Disease. Clin. Microbiol. Rev. 21: 666-685 [Abstract] [Full Text]  
  • Laohavaleeson, S., Tessier, P. R., Nicolau, D. P. (2008). Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 52: 2389-2394 [Abstract] [Full Text]  
  • Ogawa, M., Suzuki, J.-i., Hishikari, K., Takayama, K., Tanaka, H., Isobe, M. (2008). Clarithromycin Attenuates Acute and Chronic Rejection Via Matrix Metalloproteinase Suppression in Murine Cardiac Transplantation. J Am Coll Cardiol 51: 1977-1985 [Abstract] [Full Text]  
  • Traunmuller, F., Zeitlinger, M., Zeleny, P., Muller, M., Joukhadar, C. (2007). Pharmacokinetics of Single- and Multiple-Dose Oral Clarithromycin in Soft Tissues Determined by Microdialysis. Antimicrob. Agents Chemother. 51: 3185-3189 [Abstract] [Full Text]  
  • Brook, I., Giraldo, D. E, Germana, A., Nicolau, D. P, Jackson, W. E, Elliott, T. B, Thakar, J. H, Shoemaker, M. O, Ledney, G D. (2005). Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without 60Co gamma-photon irradiation. J Med Microbiol 54: 1157-1162 [Abstract] [Full Text]  
  • Sun, H. K., Lee, S. Y., Banevicius, M. A., Du, X., Maglio, D., Nicolau, D. P. (2005). Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother 56: 559-565 [Abstract] [Full Text]  
  • Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother. 49: 188-194 [Abstract] [Full Text]  
  • Pelton, S. I., Hammerschlag, M. R. (2005). Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children. CLIN PEDIATR 44: 1-17  
  • Giamarellos-Bourboulis, E. J., Adamis, T., Laoutaris, G., Sabracos, L., Koussoulas, V., Mouktaroudi, M., Perrea, D., Karayannacos, P. E., Giamarellou, H. (2004). Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48: 93-99 [Abstract] [Full Text]  
  • Gotfried, M. H., Danziger, L. H., Rodvold, K. A. (2003). Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J Antimicrob Chemother 52: 450-456 [Abstract] [Full Text]  
  • Zhanel, G. G., DeCorby, M., Noreddin, A., Mendoza, C., Cumming, A., Nichol, K., Wierzbowski, A., Hoban, D. J. (2003). Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52: 83-88 [Abstract] [Full Text]  
  • Hardy, R. D., Rios, A. M., Chavez-Bueno, S., Jafri, H. S., Hatfield, J., Rogers, B. B., McCracken, G. H., Ramilo, O. (2003). Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of Mycoplasma pneumoniae-Induced Pneumonia. Antimicrob. Agents Chemother. 47: 1614-1620 [Abstract] [Full Text]  
  • Peric, M., Bozdogan, B., Jacobs, M. R., Appelbaum, P. C. (2003). Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical Isolates. Antimicrob. Agents Chemother. 47: 1017-1022 [Abstract] [Full Text]  
  • Elliott, T. B., Brook, I., Harding, R. A., Bouhaouala, S. S., Shoemaker, M. O., Knudson, G. B. (2002). Antimicrobial Therapy for Bacillus anthracis-Induced Polymicrobial Infection in 60Co {gamma}-Irradiated Mice. Antimicrob. Agents Chemother. 46: 3463-3471 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»